| Dr Mamatha Reddy Gadarla, MD | |
|
97 West Parkway, Pompton Plains, NJ 07444-3459 | |
| (973) 831-5000 | |
| Not Available |
| Full Name | Dr Mamatha Reddy Gadarla |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 25 Years |
| Location | 97 West Parkway, Pompton Plains, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124167879 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA08121700 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of New Jersey | Bloomfield, NJ | Hospice |
| St Joseph's Hospital And Medical Center | Paterson, NJ | Hospital |
| St Joseph's Healthcare And Rehab Center | Cedar grove, NJ | Nursing home |
| Entity Name | St Josephs Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497791297 PECOS PAC ID: 9739171984 Enrollment ID: O20040330001612 |
News Archive
The U.S. Census Bureau released a report today that estimates that 45.7 million Americans were uninsured in 2007 compared to 47 million in 2006. While the report shows a slight drop in the number of uninsured, it underscores the urgent need to expand access to health coverage, according to Consumers Union, nonprofit publisher of Consumer Reports.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.
Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.
With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.
› Verified 5 days ago
| Entity Name | Practice Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427016385 PECOS PAC ID: 5890703177 Enrollment ID: O20060330000690 |
News Archive
The U.S. Census Bureau released a report today that estimates that 45.7 million Americans were uninsured in 2007 compared to 47 million in 2006. While the report shows a slight drop in the number of uninsured, it underscores the urgent need to expand access to health coverage, according to Consumers Union, nonprofit publisher of Consumer Reports.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.
Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.
With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.
› Verified 5 days ago
| Entity Name | Essex Primary Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205240025 PECOS PAC ID: 1850607995 Enrollment ID: O20150903001197 |
News Archive
The U.S. Census Bureau released a report today that estimates that 45.7 million Americans were uninsured in 2007 compared to 47 million in 2006. While the report shows a slight drop in the number of uninsured, it underscores the urgent need to expand access to health coverage, according to Consumers Union, nonprofit publisher of Consumer Reports.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.
Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.
With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.
› Verified 5 days ago
| Entity Name | St Josephs Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205425519 PECOS PAC ID: 8628470325 Enrollment ID: O20210716000520 |
News Archive
The U.S. Census Bureau released a report today that estimates that 45.7 million Americans were uninsured in 2007 compared to 47 million in 2006. While the report shows a slight drop in the number of uninsured, it underscores the urgent need to expand access to health coverage, according to Consumers Union, nonprofit publisher of Consumer Reports.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.
Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.
With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mamatha Reddy Gadarla, MD 105 Jesse Court, Montville, NJ 07045-3459 Ph: (973) 265-8729 | Dr Mamatha Reddy Gadarla, MD 97 West Parkway, Pompton Plains, NJ 07444-3459 Ph: (973) 831-5000 |
News Archive
The U.S. Census Bureau released a report today that estimates that 45.7 million Americans were uninsured in 2007 compared to 47 million in 2006. While the report shows a slight drop in the number of uninsured, it underscores the urgent need to expand access to health coverage, according to Consumers Union, nonprofit publisher of Consumer Reports.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.
Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.
With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.
› Verified 5 days ago
Dr. Anirudh Kapoor, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 97 W Parkway, Pompton Plains, NJ 07444 Phone: 908-522-2829 Fax: 908-522-6147 | |
Dr. Krishna Duvvuri, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 476 Newark Pompton Turnpike, Pompton Plains, NJ 07444 Phone: 973-248-8403 Fax: 973-839-6015 | |
Dr. Glenn Wm Patterson, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 620 Forest Gln, Pompton Plains, NJ 07444 Phone: 845-589-0800 Fax: 855-316-2753 | |
Dr. Sarah Khan, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 242 W Parkway, Pompton Plains, NJ 07444 Phone: 862-248-8165 Fax: 862-248-8166 | |
Dr. Jesse V Wassner, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cedar Crest Dr, Pompton Plains, NJ 07444 Phone: 973-831-3540 Fax: 973-831-3503 | |
Andrew Armanious, Internal Medicine Medicare: Medicare Enrolled Practice Location: 242 W Parkway, Pompton Plains, NJ 07444 Phone: 973-831-7455 Fax: 973-831-7585 |